These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10708292)

  • 21. The CD4 antigen: physiological ligand and HIV receptor.
    Sattentau QJ; Weiss RA
    Cell; 1988 Mar; 52(5):631-3. PubMed ID: 2830988
    [No Abstract]   [Full Text] [Related]  

  • 22. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.
    Cease KB; Margalit H; Cornette JL; Putney SD; Robey WG; Ouyang C; Streicher HZ; Fischinger PJ; Gallo RC; DeLisi C
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4249-53. PubMed ID: 2438696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4+ lymphocyte function with early human immunodeficiency virus infection.
    Gurley RJ; Ikeuchi K; Byrn RA; Anderson K; Groopman JE
    Proc Natl Acad Sci U S A; 1989 Mar; 86(6):1993-7. PubMed ID: 2564677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental treatments for HIV-infected patients.
    Am Fam Physician; 1989 Jun; 39(6):330. PubMed ID: 2729046
    [No Abstract]   [Full Text] [Related]  

  • 25. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 26. Army expected to clear AIDS scientist.
    Science; 1993 Jul; 261(5117):19. PubMed ID: 8316847
    [No Abstract]   [Full Text] [Related]  

  • 27. New vaccines for the prevention and treatment of disease.
    Morrow WJ; Köhler H
    Ann Med Interne (Paris); 1991; 142(6):429-33. PubMed ID: 1772184
    [No Abstract]   [Full Text] [Related]  

  • 28. Human trials of AIDS vaccines: novel means of passive and active immunotherapy.
    Dalgleish AG
    AIDS; 1988; 2 Suppl 1():S129-31. PubMed ID: 3147663
    [No Abstract]   [Full Text] [Related]  

  • 29. Soluble CD4: another therapeutic option in HIV infection.
    Lancet; 1990 May; 335(8698):1128-30. PubMed ID: 1971867
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of influenza vaccination on disease progression among HIV-infected persons.
    Sullivan PS; Hanson DL; Dworkin MS; Jones JL; Ward JW;
    AIDS; 2000 Dec; 14(17):2781-5. PubMed ID: 11125897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen processing and CD4+ T cell depletion in AIDS.
    Germain RN
    Cell; 1988 Aug; 54(4):441-4. PubMed ID: 2969773
    [No Abstract]   [Full Text] [Related]  

  • 32. Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals.
    Picard O; Lebas J; Imbert JC; Bigel P; Zagury D
    J Acquir Immune Defic Syndr (1988); 1991; 4(6):641-3. PubMed ID: 1673716
    [No Abstract]   [Full Text] [Related]  

  • 33. HHS fumbles ball on AIDS vaccine trial.
    Science; 1993 Jul; 261(5118):151. PubMed ID: 8327883
    [No Abstract]   [Full Text] [Related]  

  • 34. Army clears Redfield--but fails to resolve controversy.
    Cohen J
    Science; 1993 Aug; 261(5123):824-5. PubMed ID: 8346432
    [No Abstract]   [Full Text] [Related]  

  • 35. Army to test only MicroGeneSys vaccine.
    Science; 1993 Aug; 261(5123):819. PubMed ID: 8346429
    [No Abstract]   [Full Text] [Related]  

  • 36. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
    AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.
    Günthard HF; Gowland PL; Schüpbach J; Fung MS; Böni J; Liou RS; Chang NT; Grob P; Graepel P; Braun DG
    J Infect Dis; 1994 Dec; 170(6):1384-93. PubMed ID: 7995976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human recombinant soluble CD4 therapy.
    Gerety RJ; Hanson DG; Thomas DW
    Lancet; 1989 Dec 23-30; 2(8678-8679):1521. PubMed ID: 2574789
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
    Sailaja G; Husain S; Nayak BP; Jabbar AM
    J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine.
    Stephens DM; Eichberg JW; Haigwood NL; Steimer KS; Davis D; Lachmann PJ
    J Gen Virol; 1992 May; 73 ( Pt 5)():1099-106. PubMed ID: 1375277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.